Drug Discovery & Pharmaceuticals

RSS

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

Penn researchers develop ApexGO to enhance promising antibiotic candidates

Researchers at the University of Pennsylvania have developed ApexGO, a novel, AI-powered method for turning promising but imperfect antibiotic candidates into more potent ones.

13 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk, selective modulation, and transcription factor-mediated gene suppression.

From INDIGO Biosciences, Inc. 11 May 2026

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (IDC), an international product development company, today announced that their Intranasal Drug Delivery Platform has reached a new milestone, with its lead single-use nasal dry powder device now available for commercial partnerships.

From Hovione 11 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

Bruker unveils new NMR products and workflow solutions at ENC 2026

At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR.

From Bruker 8 May 2026

Cranberry juice may help stop antibiotic resistance in UTIs

Cranberry juice potentiates fosfomycin against UPEC, lowering resistance rates and modifying bacterial absorption pathways for improved antibiotic efficacy.

7 May 2026

Organic lithium salts may affect many cellular level changes in Alzheimer's disease

Lithium chloride may affect many cellular level changes in Alzheimer's disease, a new study from the University of Eastern Finland (UEF) shows.

6 May 2026

New inhibitor design provides a blueprint for effective malaria treatments

Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

6 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial.

6 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026

Technique will turbocharge new medicines to combat antimicrobial resistance

...

29 Apr 2026

Study provides roadmap for safer pharmaceutical analysis methods

A new doctoral thesis at Karlstad University provides increased understanding of how medicines can be analysed more reliably and safely.

28 Apr 2026

New computational protocol accelerates drug discovery for Chagas disease

Researchers at the University of Kent have established a computational protocol that could accelerate the development of more effective treatments for life-threatening parasitic infections such as Chagas disease, by enabling scientists to accurately identify reactions that can result in successful drug candidates without the need for trial and error.

25 Apr 2026

AI model rapidly designs new antibiotic to fight resistant bacteria

Researchers at McMaster University have developed a new generative artificial intelligence (AI) model capable of drastically speeding up drug discovery - and, in early tests, it has already designed a brand-new antibiotic.

23 Apr 2026

Researchers receive NIH grant to accelerate Alzheimer's drug discovery efforts

Dr. Damian Young, investigator at Texas Children's Duncan Neurological Research Institute (Duncan NRI) and director of the Center for Drug Discovery at Baylor College of Medicine, along with collaborators has been awarded a $6.7 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to develop new approaches to rapidly identify potential treatments for Alzheimer's disease and related dementias with the goal of accelerating the discovery of new therapies.

23 Apr 2026

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced the launch of STORganoid™, an ambient-temperature preservation solution for organoids and spheroids.

From Atelerix Ltd 21 Apr 2026

Drug Discovery & Pharmaceuticals

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

Penn researchers develop ApexGO to enhance promising antibiotic candidates

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Bruker unveils new NMR products and workflow solutions at ENC 2026

Cranberry juice may help stop antibiotic resistance in UTIs

Organic lithium salts may affect many cellular level changes in Alzheimer's disease

New inhibitor design provides a blueprint for effective malaria treatments

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

NIH awards $3.9 million grant to develop a non-opioid pain treatment

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

Metabolic rewiring could help CAR-T cells fight solid tumors

Technique will turbocharge new medicines to combat antimicrobial resistance

Study provides roadmap for safer pharmaceutical analysis methods

New computational protocol accelerates drug discovery for Chagas disease

AI model rapidly designs new antibiotic to fight resistant bacteria

Researchers receive NIH grant to accelerate Alzheimer's drug discovery efforts

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Latest eBooks

Industry Focus eBook - Pharmaceutical manufacturing (3rd edition)

A best-practice guide for laboratory services in oncology trials

Industry Focus eBook - Oncology (1st Edition)

Editorial Focus eBook - Proteomics

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware